リスク保有患者におけるバリシチニブの安全性: リウマチおよび皮膚科領域の臨床試験解析
Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w
Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.